cas 1001-26-9|| where to buy Ethyl 3-ethoxy-2-propenoate

製品名:Ethyl 3-ethoxy-2-propenoate

IUPAC Name:ethyl (2E)-3-ethoxyprop-2-enoate

包装単位	有効在庫	価格（USD）
CM247241-250g	in stock	Ǝǜ
CM247241-500g	in stock	ƿũǶ
CM247241-1000g	in stock	ȡƛȡ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1001-26-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1001-26-9; 分子式:C7H12O3; 融点:-; SMILESコード:O=C(OCC)/C=C/OCC; 密度:

: カタログ番号:CM247241; 分子量:144.17; 沸点:195.5°C at 760 mmHg; MDL番号:MFCD00009863; 保管方法:Store at 2-8°C.

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.